Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax

Abivax SA Sponsored ADR (NASDAQ:ABVX) – Leerink Partnrs cut their FY2025 earnings per share estimates for Abivax in a report issued on Wednesday, July 23rd. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.65) per share for the year, down from their prior forecast of ($3.36). The consensus estimate for Abivax’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Abivax’s Q4 2025 earnings at ($1.75) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.89) EPS and FY2029 earnings at $1.16 EPS.

A number of other research firms also recently commented on ABVX. Guggenheim boosted their target price on Abivax from $50.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research report on Friday, July 18th. Piper Sandler boosted their target price on Abivax from $42.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday. Lifesci Capital boosted their target price on Abivax from $45.00 to $101.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Leerink Partners set a $74.00 target price on Abivax and gave the stock an “outperform” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Abivax has an average rating of “Buy” and an average target price of $80.00.

Abivax Price Performance

Abivax stock opened at $66.49 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.25 and a current ratio of 1.25. Abivax has a 1-year low of $4.77 and a 1-year high of $72.90. The stock’s 50 day moving average price is $11.03 and its 200 day moving average price is $8.11.

Hedge Funds Weigh In On Abivax

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Abivax in the fourth quarter worth $85,000. Guggenheim Capital LLC acquired a new position in shares of Abivax in the fourth quarter worth $92,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Abivax in the fourth quarter worth $110,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.